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Background: Metformin an oral hypoglycemic has been widely used as a fist line of treatment of Type II Diabetes
but in a very high dose 2–3 times a day and moreover suffers from a number of side effects like lactic acidosis,
gastric discomfort, chest pain, allergic reactions being some of them. The present work was conducted with the
aim of sustaining the release of metformin so as to decrease its side effects and also reduce its dosing frequency
using a novel delivery system niosomes (non-ionic surfactant vesicles). Non-ionic surfactant vesicles of different
surfactants were prepared using thin film hydration technique and were investigated for morphology, entrapment,
in-vitro release, TEM (transmission electron microscopy) and physical stability. Optimized formulation was further
studied for the effect of Surfactant concentration, DCP (Dicetyl phosphate), Surfactant: cholesterol ratio and volume
of hydration. The release studies data was subjected to release kinetics models.
Results: The prepared vesicles were uniform and spherical in size. Optimized formulation MN3 entrapped the drug with
84.50±0.184 efficiency in the vesicles of the size 487.60±2.646 and showed the most sustained release of 73.89±0.126.
Also it was resulted that 100 molar concentration of cholesterol and surfactant, Presence of DCP, equimolar ratio of
span 60: cholesterol and 15 ml of volume of hydration were found to be optimum for miosome preparation.
Conclusions: The present work concluded metformin loaded niosomes to be effective in sustaining the drug release
leading to decreased side effects and increased patient compliance.
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With the advent of therapeutics, oral delivery is the most
widely used and the most convenient route of drug delivery.
Despite of phenomenal advances in other dosage routes viz.
injectable, inhalable, transdermal, nasal, oral delivery still re-
main well ahead of the pack as the preferred delivery route.
Higher concentration is focused in making the oral formu-
lations viable if it is not immediately viable, than in plump-
ing for an alternative delivery method. The top 50 drugs
selling in the world have 84% oral delivery [1]. Variety of
approaches have been tried to enhance the oral bioavailabil-
ity of poorly soluble drugs using the excipients with
approved or GRAS (generally regarded as safe) status.
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distribution, and reproduction in any mediumand milling; nanosizing into nanoparticles by various tech-
niques with high-pressure homogenization being one of
most efficient; crystal engineering of polymorphs, hydrates,
solvates, co-crystals, supercritical fluid and sonocrystalliza-
tion; solid dispersions developed by melt-mixing, solvent
evaporation, supercritical fluid and melt extrusion; solubil-
izing ability of cyclodextrins; solid lipid nanoparticles
prepared by high-pressure homogenization and microemul-
sion technology and other colloidal drug delivery systems
including emulsions, microemulsions, self-emulsified and
self-microemulsified drug delivery systems, liposomes etc.
have been widely researched for enhancement of oral bio-
availability [2]. Other attempts of enhancing oral bioavail-
ability include Solid lipid nanoparticles, mucoadhesive
delivery system, lipid digestion models, Supersaturatable
Formulations, nanoemulsion, nanocapsules, fast-dispersing
dosage forms and pH-sensitive supramolecular assemblies
[3-10].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Sankhyan and Pawar DARU Journal of Pharmaceutical Sciences 2013, 21:7 Page 2 of 8
http://www.darujps.com/content/21/1/7Diabetes is a group of chronic carbohydrate metabol-
ism disorders resulting from diminished or absent action
of insulin by altered secretion, decreased insulin efficacy
or combination of both the factors leading to hypergly-
cemia. Type II diabetes is the most common type count-
ing about 90-95% of the diagnosed cases, characterized
with normal or even excess of insulin levels with insulin
resistance being the major cause of increased glucose
levels [11]. Metformin a biguanide enhances insulin sen-
sitivity, found to be effective in impaired glucose toler-
ance, obese patients and patients with cardiovascular
diseases and is used as first line of drug in treatment of
Type II diabetes [12].
The oral bioavailability of Metformin is 50-60% as it is
BCS (Biopharmaceutical Classification System) class III
drug and has site-specific absorption in the GI tract [13].
The drug has negligible plasma protein binding, rela-
tively short half life of 1.5-4.5 hours and requires admin-
istration of 500 mg dose two or three times a day [14].
Moreover the drug suffers from serious but rare side
effects of lactic acidosis with 50% mortality, chest pain,
allergic reactions accompanied by high incidences of
concomitant gastrointestinal symptoms such as diarrhea,
abdominal discomfort, vomiting, stomachache, headache
and lethargy [15]. Researchers endeavored for years to
enhance the oral bioavailability, sustain the drug release
for better patient compliance and reduced side effects of
the most widely used oral hypoglycemic Metformin. The
conventional dosage form of Metformin i.e. tablet has
been modified by various approaches to get the desired
results. Matrix tablets with sustained release have been
prepared using hydroxypropyl methyl cellulose as a
hydrophilic polymer, hydrophilic synthetic polymers and
hydrophobic natural polymers and by incorporation of
lipophillic waxes by melt granulation [14,16]. With the
view to enhance patient compliance taste masked tablets
and oro-dispersible tablets have also been formulated,
also the FDA (Food and Drug Administration) has
approved metformin-glipizide tablets for oral suspen-
sion, metformin-glyburide oral solution and linagliptin-
metformin hydrochloride tablets [17-19]. Niosomes are
non ionic surfactant vesicles having lamellar structure
formed by self assembly of surfactant molecules. To im-
prove the oral bioavailability of poorly water soluble
drug like griseofulvin, the noisome (vesicular) system
was developed [20]. In another report, the polysacchar-
ide coated noisomes of propranolol HCl was developed
for the oral drug delivery and studied the effect of poly-
saccharide cap using hydrophobic anchors on the non
ionic surfactant vesicles [21]. The only novel delivery
system so far utilized for the delivery of metformin is
mucoadhesive ispaghula-sodium alginate beads [22].
Niosomes have been used to deliver a number of drugs
and have shown pronounced benefits of enhancedbioavailability, sustained release, targeted delivery,
decreased side effects, high stability, easy modification,
and so on [23]. In the present investigation niosomes
have been prepared to enhance oral bioavailability of
class III antidiabetic drug. The nonionic surfactant vesi-
cles have been prepared and evaluated for entrapment
efficiency, in vitro drug release, particle size, zeta poten-
tial, TEM. Also the effect of various parameters viz.
molar concentration and molar ratio of cholesterol and
surfactant, presence of DCP and volume of hydration
was studied on the various evaluated parameters. The
studied system is developed for efficient treatment of
Type II diabetes.
Methods
Metformin was a kind gift sample from Matrix Laborator-
ies (Hyderabad, India). Cholesterol was supplied by Fisher
Scientific (Mumbai, India). The non-ionic surfactants viz.
Span 20, Span 40, Span 60, Span 80, Tween 20, Tween 80
and Brij 30 were purchased from Loba Chemie Pvt. Ltd.
(Mumbai, India). Tween 60 was procured from Sisco Re-
search Laboratories Pvt. Ltd. (Mumbai, India) and HPLC
chloroform was provided by Merck Specialities Pvt. Ltd.
(Mumbai, India). All the ingredients used in the proce-
dures were of analytical grade.
Preparation of niosomes
The nano sized vesicles were prepared using Thin Film
Hydration Method. The specified quantities of choles-
terol, non-ionic surfactant and Dicetyl Phosphate (DCP)
were completely dissolved in 10 ml HPLC chloroform
contained in a clean and dry Round Bottom Flask
(Table 1). The transparent solution was reduced to a
thin dry film using Rotary Vaccum Evaporator (Perfit,
India) at 50.00±2.00°C. Metformin was dissolved in
phosphate buffer pH 6.8 and the thin dry film was
hydrated using this buffered drug solution. The film is
allowed to hydrate for about 1 hour for the formation of
niosomes [22]. Milky dispersion is prepared which is
kept at 4°C for 24 hours for maturation of the formed
vesicles.
Entrapment efficiency
The entrapment efficiency of the matured niosomes was
determined using centrifugation method. The measured
volume 5 ml of the prepared dispersion was centrifuged
using cooling centrifuge (RIS-24BL, REMI India) at 6°C
for 1 hour to separate the free drug from niosomes. The
niosomes formed a cake floating at the top of tube and
clear solvent containing the unentrapped drug remained
at the bottom. The cake was resuspended in 5 ml phos-
phate buffer pH 6.8 and the process was repeated twice
by centrifugation for 30 minutes to ensure complete re-
moval of free drug. After suitable dilution with
Table 1 Composition (molar ratio), entrapment efficiency and particle size of metformin niosomes
Formulation code Cholesterol Surfactant Dicetyl phosphate (mg) Entrapment* efficiency (%) Particle size* (nm)
MN1 250 Span 60 (250) 5 85.16±0.12 574.33±2.08
MN2 250 Span 60 (250) - 87.12±0.05 636.00±2.65
MN3 100 Span 60 (100) 5 84.50±0.18 487.60±2.65
MN4 100 Span 60 (100) - 86.51±0.15 504.66±2.52
MN5 75 Span 60 (75) 5 83.66±0.08 388.0±3.61
MN6 75 Span 60 (75) - 84.71±0.05 496.66±3.51
MN7 250 Span 40 (250) 5 83.91±0.01 565.33±2.52
MN8 250 Span 40 (250) - 85.07±0.08 624.67±2.08
MN9 100 Span 40 (100) 5 83.71±0.12 462.33±2.08
MN10 100 Span 40 (100) - 84.88±0.11 496.33±1.53
MN11 75 Span 40 (75) 5 84.56±0.08 378.67±1.53
MN12 75 Span 40 (75) - 86.63±0.02 484.67±1.53
*Mean ± SD, n = 3.
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the determination of free drug spectrophotometrically
by UV-visible Spectrophotometer (AU-2701, Systronics,
Mumbai, India) [24]. The entrapment efficiency was cal-
culated using the formula
PercentEntrapmentEfficiency
¼ InitialDrug Dið Þ  Unentrappeddrug Duð Þ
InitialDrug Dið Þ X100
In-vitro drug release
The in-vitro drug release pattern was studied using
modified USP dissolution apparatus Ι. Samples were
placed on the dialysis membrane previously soaked over-
night in phosphate buffer pH 6.8 and attached to lower
end of a glass tube. The tubes were immersed in dissol-
ution vessel containing phosphate buffer pH 6.8 main-
tained at 37±0.5°C. Samples were withdrawn at regular
interval of time and replaced with equal amount of buf-
fer to maintain sink condition [25]. The samples were
analyzed by UV/Visible spectrophotometer (AU-2701,
Systronics, Mumbai, India) for the drug release pattern.
The study was continued upto 8 hours.
Particle size and zeta potential
The particle size of the non-ionic surfactant vesicles was
determined by dynamic light scattering technique also
known as photon correlation spectroscopy using Zetasi-
zer Nano ZS-90 (Malvern Instruments Ltd., UK) [26].
The samples diluted suitably by filtered water (0.5 mi-
crometer filter- Himedia) were placed in the cuvettes
and the procedure was carried out at 90° angle and
temperature 25°C to determine the size of the particles
in the range of 0.6nm to 3 microns. The zeta potential
was determined using combination of laser Dopplervelocimetry and phase analysis light scattering by
Zetasizer Nano ZS-90 (Malvern Instruments Ltd.; UK).
The diluted niosome dispersions were located in zeta
meter cell for determination of electrophoretic mobility
[27]. All the experiments were performed in triplicate.
Transmission electron microscopy
The morphology of the vesicles was examined by trams-
mission electron microscopy (TEM). A drop of niosomal
dispersion was diluted 10 times and was stratified onto a
carbon-coated copper grid for 1 minute and excess was
removed by filter paper. A drop of 2% phosphotungstic
acid solution was stratified to stain the vesicles; excess
was removed by a tip of filter paper and left to air dry.
The grid was observed by transmission electron micros-
copy (Hitachi, H-7500) and by using imaging viewer
software the images were analyzed and captured [28].
Drug release kinetic data analysis
The release data obtained from various formulations was
studied further for fitness of data in different kinetic
models like Zero order, First order, Higuchi and
Korsmeyer-Peppas release models [29].
Physical stability testing
Physical stability of the niosomes was studied by leach-
ing of the drug from the vesicles in the native prepared
form i.e. dispersion stored under refrigeration. The opti-
mized dispersion with the composition of cholesterol
and span in 100:100 molar ratio with DCP was sealed in
glass vials and stored under refrigeration temperature
(2-8°C) for a period of 90 days. Samples were withdrawn
at definite intervals of time and the amount of drug
remaining was calculated by the method employed for
entrapment efficiency determination [30].
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Span 20, Span 80, Tween 20, Tween 60, Tween 80 and
Brij 30 did not formed thin and dry film at the round
bottom flask so were not used further in the study.
Thereby Span 40 and Span 60 were used for the prepar-
ation and evaluation in the study.
Morphology
The prepared niosomal solution was a homogeneous
dispersion and after maturation of 24 hours was studied
under the microscope for morphological evaluation. The
vesicles were uniform, spherical in shape with traces of
aggregation. The formulations prepared with inclusion
of DCP were found to be free from aggregation.
Entrapment efficiency
The amount of drug loaded in the vesicles was determined
by centrifugation method which separates the entrapped
and the unentrapped drug. The percent entrapment effi-
ciency was calculated and was found to be in the range of
83.66±0.08-87.12±0.05 (Table 1).
In-vitro release
The release pattern of the drug from the niosomes was
studied using modified USP dissolution apparatus Ι. The
formulations presented sustained release upto 8 hours
with MN3 having the most sustained release of 73.89
±0.13 at the end of 8 hours. On the basis of most sus-
tained release and sufficient entrapment of 84.50±0.18
MN3 was selected as the optimized formulation (Figure 1)
(Figure 2).
Particle size and zeta potential
The average vesicular size of niosomes of all the batches
was measured in the range of 388.0±3.61-644.67±2.08
(Table 1). Also the surface charge was studied by zeta
potential measurement. The niosomes were found to beFigure 1 In vitro drug release pattern of metformin niosomes using Sstabilized by large negative values of zeta potential and
the polydispersity index (PDI) was 0.123.
Transmission electron microscopy
The TEM photomicrographs clearly indicate that vesi-
cles were uniform, unilamellar and spherical in shape.
Also the positive staining showed the drug to be concen-
trated in the core of the vesicles with drug free bilayer
(Figure 3).
Release kinetics
The study of drug release kinetics showed that in all the
formulations the best fit model was found to be
Korsmeyer-Peppas with ‘n’ smaller than 0.45 suggesting
the Fickian diffusion release mechanism for the drug. For-
mulation MN3 showed the lowest release of 73.89±0.13 in
8 hours and had correlation coefficient (r =0.996)
(Table 2).
Physical stability
The formulation investigated for physical stability stud-
ies showed the residual drug content in the niosomes to
be 77.61± 0.22 at the end of three months. The results
concluded that almost 99% of the drug was retained
upto 1 month and at the end of the study 91.84% drug
was retained by the formulation (Table 3).
Discussion
Effect of type of surfactants
The effect of non-ionic surfactant was studied on the en-
trapment efficiency, particle size and in-vitro release of
the prepared niosomes. Span 60 and Span 40 were the
two surfactants used in the study and the formulations
were prepared by varying their concentrations to the
same extent. Span 60 preceded Span 40 in terms of in-
vitro release and entrapment efficiency by presenting the
most sustained release in all the prepared batches andpan 60.
Figure 2 In vitro drug release pattern of metformin niosomes using Span 40.
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sponding formulations (Figure 1) (Figure 2). Span 60
and Span 40 has the same head group and differs in the
chain length of the alkyl chain which determines their
performance. Span 60 having longer chain length pro-
vide more stable vesicles contributing to the higher en-
trapment and delayed release. Also the ordered gel state
and higher phase transition temperature offered by Span
60 plays a significant role in the observed outcomes
[31,32]. The size of the vesicles was slightly high inFigure 3 TEM images (a) Uniform distribution; (b) Uniform spherical shaformulations prepared by Span 60 at the same molar
concentration of Span 40. This may be the repercussion
of the longer alkyl chain and its stronger interactions
with cholesterol molecules which resulted larger core
space providing larger entrapment [33]. Decreased molar
concentrations of surfactant and cholesterol reduced the
entrapment of the drug and the size which may be the
aftermath of the insufficient bilayer material to form a
strong membrane and to encapsulate the drug efficiently.
The case was not similar for the drug release anpe & size; (c) Visible membrane & dark core; (d) Uniform shape.
Table 2 Drug release kinetics profile of metformin niosomes
S. NO Formulation code Zero order First order Higuchi Korsemeyer - Peppas
r2 K r2 K r2 K r2 K n
1 MN1 0.851 24.00 0.566 0.137 0.973 7.98 0.993 1.620 0.267
2 MN2 0.855 24.35 0.564 0.139 0.973 7.97 0.995 1.629 0.264
3 MN3 0.809 23.66 0.541 0.135 0.953 9.75 0.996 1.580 0.261
4 MN4 0.779 25.86 0.506 0.142 0.937 11.51 0.968 1.629 0.204
5 MN5 0.824 27.81 0.511 0.150 0.954 11.07 0.975 1.660 0.252
6 MN6 0.821 28.82 0.500 0.153 0.946 11.76 0.968 1.601 0.336
7 MN7 0.760 28.96 0.474 0.151 0.927 13.51 0.992 1.664 0.203
8 MN8 0.759 29.94 0.469 0.153 0.928 13.90 0.998 1.676 0.216
9 MN9 0.734 32.70 0.440 0.160 0.909 16.13 0.960 1.714 0.184
10 MN10 0.767 32.54 0.454 0.161 0.925 15.19 0.969 1.717 0.195
11 MN11 0.754 34.53 0.440 0.165 0.920 16.47 0.991 1.739 0.198
12 MN12 0.769 34.65 0.450 0.165 0.932 15.79 0.992 1.751 0.202
13 MN13 0.812 30.27 0.487 0.156 0.943 12.70 0.957 1.692 0.214
14 MN14 0.814 23.35 0.538 0.135 0.939 9.86 0.959 1.589 0.203
15 MN15 0.793 25.36 0.509 0.141 0.929 11.30 0.952 1.624 0.190
16 MN16 0.702 37.27 0.405 0.170 0.883 19.50 0.963 1.766 0.156
17 MN17 0.820 23.06 0.546 0.134 0.948 9.46 0.988 1.579 0.223
18 MN18 0.820 24.69 0.535 0.139 0.954 9.91 0.976 1.606 0.235
*r2=regression coefficient, K= release rate constant, n=diffusional exponent.
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and increase or decrease in the amount of surfactant
lead to early drug loss (Table 1).
Effect of DCP
Charge inducer used was also scrutinized to corroborate its
effects on the characteristics of the vesicles. The negative
charge induced by DCP resulted in smaller size of the vesi-
cles leading to lower entrapment efficiency (Table 1).
Charge on the surface of the bilayer cause repulsive forces
which compel the vesicles to be more curved and smaller
in sizes. Smaller the size smaller will be the volume
enclosed in the core and smaller will be the amount of drug
entrapped. DCP was also found to have an advantageousTable 3 Stability of optimized metformin niosome
formulation under refrigeration temperature (2-8°C)
storage condition








*Mean ± SD, n = 3.impact in retarding the drug release rate which may be
attributed to the stability provided by it to the membrane
[34] (Figure 1) (Figure 2). DCP has reported effects of pro-
viding integrity and uniformity and preventing aggregation
and fusion which have been established in the study by the
maintenance of sustained release and evident reduction of
aggregation in photomicrographs and visual observations
[35]. Aggregation has also been lowered by sonication of
the prepared dispersion clearly visible in photomicrographs
of the vesicles.
Effect of surfactant: cholesterol ratio
The surfactant: cholesterol ratio used, plays a decisive de-
terminant of the properties and the behavior of the bilayer
of the niosomes. So to predict the consequences, different
molar ratios of surfactants were incorporated into different
batches and were investigated for the parameters of par-
ticle size, entrapment and in-vitro release. The evaluation
proposed equimolar ratio to be the most apt for develop-
ment of a superior delivery system providing all the
required features. Surfactant is the core material for bilayer
formation, but the bilayer of just the non-ionic surfactant
is not strong enough to serve as host for the drug. So chol-
esterol having a steroidal rigid structure provides the
required strength to the bilayer, despite of the fact that
cholesterol itself is incapable of layer formation [36]. When
the molar ratio of the surfactant was increased from 75:100
to 125:100 in context with cholesterol the entrapment
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optimized ratio was equimolar i.e. 100:100. The excess of
cholesterol at lower ratio tend to disrupt the regular bilayer
structure leading to lower entrapment and higher drug re-
lease caused by leakage. Irregularities in the membrane
structure added by the excess of cholesterol may have lead
to increase in the vesicular size. With the increased ratio of
the surfactant the entrapment has also improved to an
optimized level as the excess of cholesterol is compensated
by the added surfactant. At the molar ratio of 100:100 the
surfactant and the cholesterol have the best fit arrange-
ment in the bilayer serving to be efficient drug carrier. As
the cholesterol acts as the rigidizing agent having the abil-
ity to cement the leakages, its deficiency upon increasing
the ratio of the surfactant after the optimized ratio lead to
the formation of leakage points resulting in lower entrap-
ment and increased drug release [37]. The particle size has
decreased with the increasing concentration of surfactant,
may be due to bilayer formation with decreased cholesterol
content. MN14 being the optimized formulation has high-
est entrapment of 84.14±0.07, with the most sustained re-
lease of 74.37±0.22 after 8 hours and the smallest particle
size of all 481.33±3.06 nm (Table 4).
Effect of volume of hydration
Hydration of the thin dry film by the aqueous media is a
critical step and the volume used determines the result-
ing features of the niosomes. The drug used being
hydrophilic in nature was dissolved in the buffer and this
solution was used for hydration. So the volume also
altered the concentration obtained. The results showed
no specific pattern of relationship between volume and
the evaluated parameters. MN17 prepared using 15 ml
of hydrating media served to be best fit formulation with
highest entrapment and most retarded release. Any in-
crease or decrease in volume hampered the entrapment
and subsequently the release (Table 4). The possible rea-
son for such a behavior could be stated as 15 ml provid-
ing ample space for vesicle formation. The lower volume
may have lead to incomplete or distorted formation of
bilayer due to excess of material and less of space.














*Mean ± SD, n = 3.been dispersed in large volume with large interacting
area. This may have caused formation of smaller vesicles
with decreased entrapment efficiency.
The in vitro release revealed prolonged delivery of the
drug for about 8 hours which suffice the daily requirement
in Type II diabetes treatment. The sustained release is also
proven to decrease the side effects resulting from higher
drug concentrations or presence of drug at the areas other
than the target site [38]. Also the patient compliance is
enhanced by use of niosomes with the possibility of once
daily dose as compared to 2–3 doses per day. The negative
zeta potential exhibit the negative charge developed on
the surface causing the repulsive forces preserving the for-
mulation from aggregation and fusion of vesicles thereby
maintaining their integrity and uniformity [35]. The stabil-
ity testing imply minimal drug lose from the vesicles upto
3 months at refrigeration temperature. In the light of
above facts niosomes have been found to meet the
requirements for successful delivery of the drug. Further-
more successful encapsulation of the drug in niosomes
has also opened the doors for exploitation of other bene-
fits presented by this novel delivery system viz. enhanced
penetration, targeted delivery, reduced dose, protection
from harsh environment etc.
Conclusions
The investigation conclusively supported niosomes to be an
advantageous drug delivery system with high degree of en-
trapment and sustained release of the drug over extended
period of time. The results also concluded that the studied
variables have a significant impact on the entrapment and
release of drug from the niosomes. Also the Molar concen-
tration and molar ratio of cholesterol and surfactant, the
charge inducer DCP and the volume of hydration used
should be in optimized value and greatly influence the en-
trapment of drug in the vesicles and also alters the perform-
ance of niosomes. The optimized formulation (cholesterol:
surfactant, 100:100 molar concentration) with DCP (5mg)
and 15 ml volume of hydration showed the most sustained
release of drug and was found to be the best formulation.
The careful control of all the above factors allow the pro-
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quency with the greater patient compliance. Suggesting
metformin loaded niosomes to be an efficient drug carrier
system in treatment of Type II Diabetes.
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